Aurigene Pharmaceutical Services Limited

Aurigene Pharmaceutical Services Limited is a contract research, development, and manufacturing organization (CDMO) offering end-to-end solutions from discovery through commercialization. The company operates as an integrated CRO-CDMO, serving global innovative pharma and biotech companies.

Discovery Services

With over 25 years of operations, Aurigene provides small molecule discovery services spanning chemistry, biology, and integrated services across the drug discovery lifecycle—from target identification through IND filing. The organization maintains long-term partnerships with two of the top five pharmaceutical companies and operates flexibly in FTE (full-time equivalent) and/or FFS (fee-for-service) modes, both integrated and standalone.

Manufacturing & Compliance

The company operates 16 US FDA-inspected cGMP facilities across three manufacturing countries (UK, Mexico, India). To date, Aurigene has delivered 600+ lifetime discovery and CDMO projects globally, with 20 NCEs and 6 biologics commercialized.

Sustainability & Operations

Beyond science, operations are rooted in compliance, information security, quality, and sustainability. Aurigene became water-positive in 2023 and has committed to 100% renewable power by 2030, carbon neutrality in direct operations (Scope 1 & 2) by 2030, and a 12.5% reduction in indirect supply chain emissions (Scope 3) by 2030.